Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Primary Myelofibrosis × navitoclax × Clear all

Phase

Phase 1 4 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Primary Myelofibrosis 1 Neoplasms 1

Interventions

ruxolitinib 4 Early Intervention, Educational 3 fedratinib 2 Psychiatric Rehabilitation 2 Mycophenolic Acid 2 Cyclophosphamide 2 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 selinexor 1 pomalidomide 1 peginterferon alfa-2b 1 peginterferon alfa-2a 1 parsaclisib 1 navitoclax 1 luspatercept 1 liposomal amphotericin B 1 imetelstat 1 fludarabine 1 bomedemstat 1 Whole-Body Irradiation 1 Therapeutics 1 Tacrolimus 1 Ribavirin 1 Radiotherapy 1 Pharmacogenomic Testing 1 Peripheral Blood Stem Cell Transplantation 1 Palivizumab 1 Ondansetron 1 N(4)-oleylcytosine arabinoside 1 Moxifloxacin 1 Morphine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04472598 2025-02-21

TRANSFORM-1

AbbVie

Phase 3 Completed

Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡